Filtered By:
Source: Cardiovascular Therapeutics
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 39 results found since Jan 2013.
Practical Considerations in the Use of Novel Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation
This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - October 1, 2013 Category: Cardiology Authors: Steven Deitelzweig Tags: Unsolicited Review Source Type: research
Multi‐modal interventions to enhance adherence to secondary preventive medication after stroke: a systematic review and meta‐analyses
ConclusionInterventions can lead to improvement in adherence to secondary preventative medication after stroke. However, existing data is limited as several interventions, duration of follow‐up, and various definitions were used. These findings need to be interpreted with caution.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - January 30, 2016 Category: Cardiology Authors: Sukainah Al Al Shaikh, Terry Quinn, William Dunn, Matthew Walters, Jesse Dawson Tags: Original Research Article Source Type: research
Multimodal Interventions to Enhance Adherence to Secondary Preventive Medication after Stroke: A Systematic Review and Meta‐Analyses
ConclusionInterventions can lead to improvement in adherence to secondary preventative medication after stroke. However, existing data is limited as several interventions, duration of follow‐up, and various definitions were used. These findings need to be interpreted with caution.
Source: Cardiovascular Therapeutics - March 3, 2016 Category: Cardiology Authors: Sukainah Al AlShaikh, Terry Quinn, William Dunn, Matthew Walters, Jesse Dawson Tags: Original Research Article Source Type: research
Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy
ConclusionsIschemic stroke and intestinal bleeding may consecutively occur shortly after stopping dabigatran. Coagulation parameters may remain abnormal even two days after discontinuation of dabigatran. Dabigatran should be applied with caution in elderly patients with renal insufficiency who also take drugs, which enhance the absorption of dabigatran.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - September 23, 2013 Category: Cardiology Authors: Josef Finsterer, Claudia Stöllberger, Gernot Paul, Adam Bastovansky Tags: Short Communication Source Type: research
The relationship between knowledge, health literacy and adherence among patients taking oral anticoagulants for stroke thromboprophylaxis in atrial fibrillation
ConclusionSignificant correlations between health literacy, OAC knowledge and adherence were observed, and these relationships should to be considered by health professionals responsible for monitoring patients who are prescribed anticoagulants. We also observed serious gaps in OAC knowledge. Interventions designed to optimize the outcomes of anticoagulant treatment need to address these factors.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - August 1, 2017 Category: Cardiology Authors: Chanelle A Rolls, Kehinde O Obamiro, Leanne Chalmers, Luke R E Bereznicki Tags: Original Research Article Source Type: research
The relationship between knowledge, health literacy, and adherence among patients taking oral anticoagulants for stroke thromboprophylaxis in atrial fibrillation
ConclusionSignificant correlations between health literacy, OAC knowledge, and adherence were observed, and these relationships should to be considered by health professionals responsible for monitoring patients who are prescribed anticoagulants. We also observed serious gaps in OAC knowledge. Interventions designed to optimize the outcomes of anticoagulant treatment need to address these factors.
Source: Cardiovascular Therapeutics - September 25, 2017 Category: Cardiology Authors: Chanelle A. Rolls, Kehinde O. Obamiro, Leanne Chalmers, Luke R. E. Bereznicki Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Warfarin prescription in patients with non ‐valvular atrial fibrillation and one non‐gender related risk factor (CHA2DS2VASc 1 or 2): a treatment dilemma
ConclusionWe found an elevated risk of major bleeding and intracranial haemorrhage in AF individuals treated with warfarin with 1 NGR risk factor for stroke. These data call for caution when treating with warfarin these individuals.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - October 1, 2017 Category: Cardiology Authors: Gentian Denas, Giacomo Zoppellaro, Seena Padayattil Jose, Emilia Antonucci, Francesco Marongiu, Daniela Poli, Sophie Testa, Armando Tripodi, Gualtiero Palareti, Vittorio Pengo Tags: Original Research Article Source Type: research
Warfarin prescription in patients with nonvalvular atrial fibrillation and one non –gender‐related risk factor (CHA2DS2VASc 1 or 2): A treatment dilemma
ConclusionWe found an elevated risk of major bleeding and intracranial hemorrhage in NVAF individuals treated with warfarin with 1 NGR risk factor for stroke. These data call for caution when treating with warfarin these individuals.
Source: Cardiovascular Therapeutics - November 11, 2017 Category: Cardiology Authors: Gentian Denas, Giacomo Zoppellaro, Seena Padayattil Jose, Emilia Antonucci, Francesco Marongiu, Daniela Poli, Sophie Testa, Armando Tripodi, Gualtiero Palareti, Vittorio Pengo Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Non Vitamin K Oral Anticoagulants versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments yield Novel Insights
ConclusionsFor the primary‐outcome, the absolute benefits of NOACs were modest (NNT/year values being large). Reduced haemorrhagic‐stroke rates with NOACs could be due to superior embolic infarct prevention and fewer consequential haemorrhagic transformations. Among apixaban recipients, the absolute mortality benefit exceeded that for the primary‐outcome, indicating prevention of additional unrelated deaths. The substantially greater NOAC acquisition costs need viewing against probable greater safety and the avoidance of monitoring bleeding risks.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - January 4, 2016 Category: Cardiology Authors: Cyrus R Kumana, Bernard M Y Cheung, David C W Siu, Hung‐Fat Tse, Ian J Lauder Tags: Unsolicited Review Source Type: research
Non‐vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights
ConclusionsFor the primary outcome, the absolute benefits of NOACs were modest (NNT/year values being large). Reduced hemorrhagic stroke rates with NOACs could be due to superior embolic infarct prevention and fewer consequential hemorrhagic transformations. Among apixaban recipients, the absolute mortality benefit exceeded that for the primary outcome, indicating prevention of additional unrelated deaths. The substantially greater NOAC acquisition costs need viewing against probable greater safety and the avoidance of monitoring bleeding risks.
Source: Cardiovascular Therapeutics - March 3, 2016 Category: Cardiology Authors: Cyrus R. Kumana, Bernard M.Y. Cheung, David C.W. Siu, Hung‐Fat Tse, Ian J. Lauder Tags: Unsolicited Review Source Type: research
Clinical and Economic Outcomes among Elderly Myocardial Infarction Survivors in the United States
ConclusionsRisks of mortality and cardiovascular events remain high in a Medicare population surviving >1 year after a MI. Continuing healthcare costs are doubled over pre‐MI levels up to five years after an MI. Secondary prevention measures beyond the acute post‐MI period may be indicated to reduce risk and cost in this chronic disease phase.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - July 31, 2016 Category: Cardiology Authors: Erru Yang, Michael Stokes, Saga Johansson, Carl Mellstr öm, Elizabeth Magnuson, David J. Cohen, Phillip Hunt Tags: Original Research Article Source Type: research
Dipeptidyl peptidase‐4 inhibitors and cardiovascular outcomes: Meta‐analysis of randomized clinical trials with 55,141 participants
ConclusionThese findings suggest no cardiovascular harm (or benefit) with DPP‐4 inhibitors; further large‐scale CV outcome studies will resolve the issue of excess HF risk.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - April 1, 2014 Category: Cardiology Authors: Shiying Wu, Ingrid Hopper, Marina Skiba, Henry Krum Tags: Original Research Article Source Type: research
Optimal duration of dual antiplatelet therapy after drug eluting stents: Meta‐analysis of randomized trials
ConclusionDAPT continued beyond 6 months after second generation DES implantation, decreases stent thrombosis and myocardial infarction, but increases major bleeding and all‐causes mortality compared to shorter DAPT (aspirin alone). There was no difference in cardiac mortality or stroke.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - May 25, 2015 Category: Cardiology Authors: Elsayed Abo‐salem, Said Alsidawi, Hina Jamali, Mohamed Effat, Tarek Helmy Tags: Original Research Article Source Type: research
Optimal Duration of Dual Antiplatelet Therapy after Drug‐Eluting Stents: Meta‐Analysis of Randomized Trials
ConclusionDAPT continued beyond 6 months after second generation DES implantation decreases stent thrombosis and myocardial infarction, but increases major bleeding and all‐causes mortality compared to shorter DAPT (aspirin alone). There was no difference in cardiac mortality or stroke.
Source: Cardiovascular Therapeutics - September 11, 2015 Category: Cardiology Authors: Elsayed Abo‐salem, Said Alsidawi, Hina Jamali, Mohamed Effat, Tarek Helmy Tags: Original Research Article Source Type: research
Burden and prevention of adverse cardiac events in patients with concomitant chronic heart failure and coronary artery disease: a literature review
ConclusionThis study confirms that patients with concomitant HF and CAD are at elevated risk for ACEs and suggests the need for effective new antithrombotic treatments to further decrease ischemic complication rates in this population.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - February 1, 2016 Category: Cardiology Authors: Louis Lavoie, Hanane Khoury, Sharon Welner, Jean‐Baptiste Briere Tags: Unsolicited Review Source Type: research
